Nature Reviews Clinical Oncology 10, 429-430 (August 2013) | doi:10.1038/nrclinonc.2013.97
Biological markers: Tailoring treatment and trials to prognosis
Abstract
The dominant focus of precision or personalized cancer medicine has been on the discovery of predictive, companion diagnostics for the new era of targeted therapeutics. The central idea has been that the pool of patients more likely to benefit could be enriched by identifying a tumour biomarker that predicts response (or lack of response) to therapy.
No comments:
Post a Comment